N-(3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide | 1215009-04-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
• CAS: 1215009-04-3
• 化学式: C₁₅H₂₁N₃O₃S
• 分子量: 323.416
• InChiKey: LNGJCXYOMKJOMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  92.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide 、 溴丙烷 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以24%的产率得到N-(1-propyl-3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
  参考文献：
  名称：

  Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

  摘要：

  N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.

  DOI：

  10.1021/jm201091t
• 作为产物：
  描述：

  3,5-二甲基-1H-吡唑-4-胺 、 4-甲氧基-2,3,6-三甲基苯磺酰氯 在 吡啶 作用下， 以67%的产率得到N-(3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide
  参考文献：
  名称：

  Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

  摘要：

  N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.

  DOI：

  10.1021/jm201091t

文献信息

• N-Myristoyl Transferase Inhibitors
  申请人：Brand Stephen

  公开号：US20110312921A1

  公开（公告）日：2011-12-22

  The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

  本发明涉及N-杂环磺胺化合物，特别是吡唑磺胺化合物，以及它们作为N-肉豆蔻酰转移酶抑制剂的用途。
• N-MYRISTOYL TRANSFERASE INHIBITORS
  申请人：Brand Stephen

  公开号：US20160060224A1

  公开（公告）日：2016-03-03

  The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

  本发明涉及N-杂环磺酰胺化合物，特别是吡唑磺酰胺化合物，及其作为N-肉豆蔻酰转移酶抑制剂的用途。
• PYRAZOLYL DERIVATIVES
  申请人：University of Dundee

  公开号：EP2980076A1

  公开（公告）日：2016-02-03

  The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

  本发明涉及 N-杂环磺酰胺化合物，特别是吡唑磺酰胺化合物，以及它们作为 N-肉豆蔻酰转移酶抑制剂的用途。
• US9156811B2
  申请人：——

  公开号：US9156811B2

  公开（公告）日：2015-10-13
• US9828346B2
  申请人：——

  公开号：US9828346B2

  公开（公告）日：2017-11-28